Datroway (datopotamab deruxtecan) is approved in Japan as the first TROP-2 directed therapy for patients with HR positive, HER2 negative breast cancer – Daiichi Sankyo
Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or… read more.